Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors

出版年份 2017 全文链接

标题

作者

关键词

出版物

Volume 26, Issue 15_suppl, Pages 3538-3538

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-02-24

DOI

10.1200/jco.2008.26.15_suppl.3538

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started